Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Total Liabilities (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Total Liabilities readings, the most recent being $3.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 44.71% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, down 44.71%, and an annual FY2025 reading of $3.1 million, down 44.71% over the prior year.
  • Total Liabilities hit $3.1 million in Q4 2025 for Lisata Therapeutics, down from $4.6 million in the prior quarter.
  • The five-year high for Total Liabilities was $6.8 million in Q4 2023, with the low at $3.1 million in Q4 2025.
  • Median Total Liabilities over the past 3 years was $4.7 million (2023), compared with a mean of $4.9 million.
  • The sharpest move saw Total Liabilities dropped 1.61% in 2024, then tumbled 44.71% in 2025.
  • Year by year, Total Liabilities stood at $6.8 million in 2023, then dropped by 16.4% to $5.7 million in 2024, then plummeted by 44.71% to $3.1 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $3.1 million, $4.6 million, and $4.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.